Negrier S - Search Results

1

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.

Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, Philip T. Blay JY, et al. Among authors: negrier s. Cancer Res. 1990 Apr 15;50(8):2371-4. Cancer Res. 1990. PMID: 2317822

2

[Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].

Blay JY, Négrier S, Combaret V, Merrouche Y, Mercatello A, Moskovtchenko JF, Philip T, Favrot M. Blay JY, et al. Among authors: negrier s. Bull Cancer. 1992;79(1):55-65. Bull Cancer. 1992. PMID: 1520953 French.

3

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.

Négrier S, Mercatello A, Bret M, Thiesse P, Blay JY, Coronel B, Merrouche Y, Oskam R, Franks CR, Clavel M, et al. Négrier S, et al. Br J Cancer. 1992 May;65(5):723-6. doi: 10.1038/bjc.1992.152. Br J Cancer. 1992. PMID: 1586600 Free PMC article. Clinical Trial.

4

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, et al. Blay JY, et al. Among authors: negrier s. Cancer Res. 1992 Jun 15;52(12):3317-22. Cancer Res. 1992. PMID: 1596890

5

[Treatment of renal cancer in adults with interleukin 2].

Negrier S, Mercatello A, Philip T. Negrier S, et al. Rev Prat. 1992 May 15;42(10):1241-5. Rev Prat. 1992. PMID: 1609217 French.

6

Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.

Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T. Favrot MC, et al. Among authors: negrier s. J Biol Response Mod. 1990 Apr;9(2):167-77. J Biol Response Mod. 1990. PMID: 1971303

7

Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.

Favrot MC, Coze C, Combaret V, Gaspard M, Colin C, Franks C, Negrier S, Philip I, Philip T. Favrot MC, et al. Among authors: negrier s. Mol Biother. 1990 Mar;2(1):32-7. Mol Biother. 1990. PMID: 2185792 Clinical Trial.

8

Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation.

Favrot MC, Michon J, Floret D, Cochat C, Negrier S, Mathiot C, Coze C, Zucker JM, Franks CR, Bouffet E, et al. Favrot MC, et al. Among authors: negrier s. Pediatr Hematol Oncol. 1990;7(3):275-84. doi: 10.3109/08880019009033403. Pediatr Hematol Oncol. 1990. PMID: 2206868

9

[Adoptive immunotherapy with interleukin 2 in oncology].

Favrot M, Bouffet E, Négrier S, Combaret V, Philip I, Philip T. Favrot M, et al. Among authors: negrier s. Bull Cancer. 1990;77(9):925-31. Bull Cancer. 1990. PMID: 2224165 Clinical Trial. French.

10

Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

Philip T, Mercatello A, Negrier S, Philip I, Rebattu P, Kaemmerlin P, Gaspard M, Tognier E, Combaret V, Bijmann JT, et al. Philip T, et al. Among authors: negrier s. Cancer Treat Rev. 1989 Jun;16 Suppl A:91-104. doi: 10.1016/0305-7372(89)90028-5. Cancer Treat Rev. 1989. PMID: 2788510

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235 results

Search Page

Filters